International prognostic index-based outcomes for diffuse large B-cell lymphomas

Richard B. Wilder, Maria A. Rodriguez, L. Jeffrey Medeiros, Susan L. Tucker, Chul S. Ha, Jorge E. Romaguera, Barbara Pro, Mark A. Hess, Fernando Cabanillas, James D. Cox

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

BACKGROUND. We present the results of doxorubicin-based chemotherapy with or without involved-field radiotherapy for patients with diffuse large B-cell lymphoma (DLBCL) according to the international prognostic index (IPI). METHODS. From September 1988 through December 1996, 294 patients with Stage I-IV Working Formulation large B-cell or T-cell lymphomas were treated prospectively on two protocols at our center. Diagnoses were reclassified subsequently according to the new World Health Organization classification. Two-hundred and twenty-four patients had DLBCL, including 24 patients with primary mediastinal large B-cell lymphoma. Treatment consisted of a median of six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy with or without involved-field radiotherapy (median dose, 39.6 Gy). RESULTS/CONCLUSIONS. The median length of follow-up among surviving patients was 5.0 years. Patient subgroups differed from each other in terms of progression-free (P = 0,003), cause-specific (P = 0.003), and overall (P = 0.001) survival rates when analyzed by IPI. Five-year progression-free, cause-specific, and overall survival rates for 212 patients with an IPI of 0-2 were 73%, 84%, and 82%, respectively, versus only 37%, 33%, and 32% for 12 patients with an IPI of 3-4. To improve our results, we are conducting clinical trials with young DLBCL patients and with patients who are older than 60 years. The young DLBCL patients, who have more than two adverse prognostic features, are receiving high-dose chemotherapy and autologous stem cell rescue. The patients who are older than 60 years, regardless of IPI, are receiving rituximab immunotherapy and liposomal CHOP chemotherapy with or without involved-field radiotherapy.

Original languageEnglish (US)
Pages (from-to)3083-3088
Number of pages6
JournalCancer
Volume94
Issue number12
DOIs
StatePublished - Jun 15 2002

Keywords

  • Chemotherapy
  • Clinical trials
  • Diffuse large-cell lymphoma
  • International prognostic index

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'International prognostic index-based outcomes for diffuse large B-cell lymphomas'. Together they form a unique fingerprint.

Cite this